Merck, Ridgeback Biotherapeutics Complete US Molnupiravir Supply Deal with Delivery of 1.3 Million Courses
Merck & Co. (MRK) and Ridgeback Biotherapeutics said Tuesday they have completed a supply agreement with the US government by delivering 1.3 million courses of their COVID-19 medicine molnupiravir.
Merck had entered into a procurement agreement with the US government in 2021 to provide these courses of molnupiravir once it obtained emergency use authorization or approval from the US Food and Drug Administration, the companies said.
Merck has also entered into purchase and supply agreements for molnupiravir in more than 30 markets, including Australia, Canada, Korea, Japan, Thailand, Ukraine, and the UK, subject to certain regulatory and government approvals, according to a statement.
The companies also said Merck has completed manufacturing of 10 million courses of molnupiravir, with at least 20 million courses expected to be produced in 2022.